CRISPR Therapy Turns a Corner With First Cures In Sight

Just 8 years after the development of CRISPR-Cas technology, Vertex Pharmaceuticals and CRISPR Therapeutics share positive clinical data for their ex vivo CRISPR-based therapy CTX001 that points to a potential cure for two inherited blood diseases; sickle cell disease and beta-thalassemia. Read our summary of the news here.

Career CRISPR Medicine

• Freelancer | CRISPR Medicine News - Anyplace

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at editor@crisprmedicinenews.com. We love hearing from readers!

Happy Reading!

Karen

p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.